|
|||||
|
|
Assessing the risk of cervical neoplasia in the post-HPV vaccination era |
|
| Authors: | Matti Lehtinen Ville N Pimenoff Belinda Nedjai Karolina Louvanto Lisanne Verhoef Daniëlle A M Heideman Mariam El-Zein Martin Widschwendter Joakim Dillner |
| Institution: | 1. Medical Faculty, Tampere University, Tampere, Finland;2. Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden;3. Wolfson Institute of Population Health, Queen Mary University of London, London, UK;4. Medical Faculty, Tampere University, Tampere, Finland
Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland;5. Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;6. Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands;7. Division of Cancer Epidemiology, McGill University, Montreal, Canada;8. European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Hall in Tirol, Austria Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden |
| Abstract: | This review is based on the recent EUROGIN scientific session: “Assessing risk of cervical cancer in the post-vaccination era,” which addressed the demands of cervical intraepithelial neoplasia (CIN)/squamous intraepithelial lesion (SIL) triage now that the prevalence of vaccine-targeted oncogenic high-risk (hr) human papillomaviruses (HPVs) is decreasing. Change in the prevalence distribution of oncogenic HPV types that follows national HPV vaccination programs is setting the stage for loss of positive predictive value of conventional but possibly also new triage modalities. Understanding the contribution of the latter, most notably hypermethylation of cellular and viral genes in a new setting where most oncogenic HPV types are no longer present, requires studies on their performance in vaccinated women with CIN/SIL that are associated with nonvaccine HPV types. Lessons learned from this research may highlight the potential of cervical cells for risk prediction of all women's cancers. |
| Keywords: | cervical cancer epigenetics gynecological cancers human papillomavirus methylation |